Skip to content

Clinical study of liver resection combined with radio frenquency ablation for dual lobe multifocal hepatocellular carcinoma

Clinical study of liver resection combined with radio frenquency ablation for dual lobe multifocal hepatocellular carcinoma

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-14005171
Enrollment
Unknown
Registered
2014-08-25
Start date
2014-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Case series:operation resection combined with radiofrequency ablation therapy

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
16 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1) compensation cirrhosis (Child A grade); 2) Multiple liver lesions: must also meet the following three conditions: A. Preoperative combined with medical history, physical examination, laboratory examination, imaging and the final clinical diagnosis for hepatocellular carcinoma; B. To further confirm the number and size of focal lesions using contrast-enhanced ultrasound in operation; C. Pathological diagnosis after operation for primary hepatocellular carcinoma; 3) Preoperative imaging findings should also meet the following two conditions: A. Whether the main location, size, still feasible operation excision, including half liver resection or partial resection;B. Operation before imaging revealed in semi hepatectomy, other lesions smaller than 3cm in diameter, number of less than 2, or in the local mass resection, other lesions smaller than 3cm in diameter, number of less than 3; 4) Preoperative CT or MRI, ultrasound contrast imaging examination were not found in the main portal vein tumor thrombus of portal left, right, trunk or two branches in imaging tumor thrombus, need to do the corresponding half liver or local resection to clear tumor thrombus; 5) No evidence of extrahepatic metastasis; 6) Willing to participate in this clinical study and signed informed consent.

Exclusion criteria

Exclusion criteria: 1) Under the age of 16 patients; 2) Women during pregnant stage and breast-feed stage; 3) Existence of vena cava tumor thrombus, portal vein or hepatic portal vein to retain side of cancer embolus; 4) Imaging studies revealed cirrhosis is heavy, or the Child B level, C level and liver function in patients with liver cancer resection was difficult to tolerate; 5) The complications of heart, lung, kidney and other organs of serious disease, the patients who cannot tolerate operation; 6) The presence of other treatment contraindications.

Design outcomes

Primary

MeasureTime frame
Tumor size;The number of tumor;AFP;Portal vein tumor thrombus;grades of cirrhosis;Total bilirubin;Alanine aminotransferase;Albumin;Prothrombin time;activeated partial thromboplastin time;pathologic stages of tumou;

Secondary

MeasureTime frame
Hemoglobin;PLT;serum creatinine;age;

Contacts

Public ContactBo Li
cdlibo@medmail.com.cn+86 18980601470

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026